Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
NCT05997615
This study is recruiting at 8 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The study will be conducted in 4 parts and will commence with dose escalation of VIR-5500 as a monotherapy (Part 1), followed by combination escalation (Part 3a), monotherapy dose expansion (Part 2) and combination dose expansion (Part 4a).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hormone-refractory Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Astellas Pharma Global Development, Inc.
- Last updated on ClinicalTrials.gov
- October 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 4
- Duarte Cancer Center · Duarte, CA
- Lennar Foundation Cancer Center · Irvine, CA
- UCI Health Chao Family Comprehensive Cancer Center · Orange, CA
- Investigational Site Number: 403 · Palo Alto, CA
Illinois · 1
- Chicago Cancer Center · Zion, IL
Texas · 1
- Investigational Site Number: 401 · Houston, TX
Virginia · 1
- Investigational Site number: 404 · Fairfax, VA
Washington · 1
- Investigational Site Number: 400 · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.